Natixis’s Autolus Therapeutics AUTL Stock Holding History

Natixis’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,600	Closed	-$72K	–	854
2021 Q1	$72K	Buy	+12,600	New	+$93.3K	﹤0.01%	1045

Other funds holding AUTL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Natixis's AUTL Position: Q2 2021 in Review

Natixis sold out of Autolus Therapeutics (AUTL) in Q2 2021, closing a stake of 12,600 shares — an estimated $72K sold.

Natixis first reported a position in AUTL in Q1 2021 and held it in 1 quarter. The position peaked at $72K in Q1 2021. 69 funds tracked by Wall St. Rank hold AUTL as of Q2 2021.

Natixis reported no remaining Autolus Therapeutics position as of Q2 2021 after selling out during the quarter.
Natixis sold 12,600 Autolus Therapeutics shares in Q2 2021, an estimated $72K.
Natixis first reported a position in Autolus Therapeutics in Q1 2021 and held it in 1 quarter.
Natixis's Autolus Therapeutics position peaked at $72K in Q1 2021.
69 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2021.

Based on Natixis's 13F filing for Q2 2021, filed 13 Aug 2021.